« Zurück
Startseite /
MOUSE ANTI PI-3 KINASE p85 ALPHA SUBUNIT

MOUSE ANTI PI-3 KINASE p85 ALPHA SUBUNIT

ArtNr	20-783-314376
Hersteller	GENWAY
Menge	0.2 mg
Kategorie	Oncology Antibodies By Cell Type Carcinoma Glioma Hematology Leukemia Lymphoma Myeloma Melanoma Sarcoma Immunoprecipitation Western Blot Cardiovascular Research Myocardial Infarction Primary Antibodies
Typ	Antibody
Applikationen	WB, IP
Specific against	other
Host	Mouse
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	GWB-BA1A75
Similar products	20-783-314376
Lieferbar
Genway ID:	GWB-BA1A75
Specificity:	PI-3 KINASE P85 ALPHA
Isotype:	IgG1Species Cross Reactivity: Reacts with: Human Monkey Mouse RatN. B. Antibody reactivity and working conditions may vary between species.
Preparation:	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution:	Phosphate buffered saline pH7. 4
Preservative Stabilisers:		0. 09% Sodium AzideApprox. Protein Concentrations: IgG concentration 1. 0mg/ml
Immunogen:	Baculovirus expressed (Recombinant) bovine p85 alpha subunit of PI-3 kinase.
Specificity:	Recognises the bcr-homology domain of the p85 alpha subunit of bovine PI-3 kinase. Recommended Secondary Antibodies: Rabbit Anti Mouse IgGGoat Anti Mouse IgGGoat Anti Mouse IgG (H/L)Goat Anti Mouse IgG IgA IgMHuCAL Anti Mouse IgG1Goat Anti Mouse IgG (Fc)Sheep Anti Mouse IgG (H/L)
Function:	Binds to activated (phosphorylated) protein-tyrosine kinases through its SH2 domain and acts as an adapter mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Subunit structureHeterodimer of a p110 (catalytic) and a p85 (regulatory) subunits. Interacts with phosphorylated LAT LAX1 TRAT1 and LIME1 upon TCR and/or BCR activation. Interacts with CBLB. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with SOCS7. Interacts with IRS1 and phosphorylated IRS4. Interacts with NISCH RUFY3 and HCST By similarity.
Domain:	The SH3 domain mediates the binding to CBLB By similarity. Post-translational modificationPolyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation By similarity. Sequence similaritiesBelongs to the PI3K p85 subunit family. Contains 1 Rho-GAP domain. Contains 2 SH2 domains. Contains 1 SH3 domain. 1. Sim E. et al. (1983) Monoclonal antibodies against complement control protein factor H (beta 1H). Journal? 3: 1119-1131. 2. Alsenz J. et al. (1985) Structural and functional analysis of the complement component Factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem. J. 232: 841-850. 3. Fontaine M. et al. (1989) Truncated forms of human complement Factor H. Biochem. J. 258: 927-930.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

Sicherheitsdatenblatt anfordern

Einfache Bestellung Periodische Bestellung

Menge: 0.2 mg

lieferbar

Lieferung vsl. bis 11.09.2025

Express-Lieferung: 7 Tage sparen

Vergleichen

Auf den Wunschzettel

Angebot anfordern